{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Anti-SARS-CoV-2+Infection&page=3",
    "query": {
      "condition": "Anti-SARS-CoV-2 Infection",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 57,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Anti-SARS-CoV-2+Infection&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Anti-SARS-CoV-2+Infection&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T18:31:27.672Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04494724",
      "title": "Clazakizumab vs. Placebo - COVID-19 Infection",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19 Infection"
      ],
      "interventions": [
        {
          "name": "Clazakizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Methodist Hospital Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2020-07-13",
      "completion_date": "2021-07-31",
      "has_results": false,
      "last_update_posted_date": "2020-07-31",
      "last_synced_at": "2026-10-07T18:31:27.672Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04494724"
    },
    {
      "nct_id": "NCT04433949",
      "title": "Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumonia",
        "Severe Acute Respiratory Syndrome",
        "Symptomatic COVID-19 Infection Laboratory-Confirmed"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Low Dose Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2020-06-23",
      "completion_date": "2024-05-30",
      "has_results": false,
      "last_update_posted_date": "2023-08-14",
      "last_synced_at": "2026-10-07T18:31:27.672Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04433949"
    },
    {
      "nct_id": "NCT04524507",
      "title": "Coronavirus Disease 2019 (COVID-19) Antibody Plasma Research Study in Hospitalized Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "High-titer Convalescent COVID-19 Plasma (CCP1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard-titer Convalescent COVID-19 plasma (CCP2)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 56,
      "start_date": "2020-08-27",
      "completion_date": "2021-06-04",
      "has_results": true,
      "last_update_posted_date": "2021-12-03",
      "last_synced_at": "2026-10-07T18:31:27.672Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04524507"
    },
    {
      "nct_id": "NCT04498273",
      "title": "COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Apixaban 2.5 MG",
          "type": "DRUG"
        },
        {
          "name": "Apixaban 5MG",
          "type": "DRUG"
        },
        {
          "name": "Aspirin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Frank C Sciurba",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 657,
      "start_date": "2020-09-07",
      "completion_date": "2021-08-05",
      "has_results": true,
      "last_update_posted_date": "2022-02-17",
      "last_synced_at": "2026-10-07T18:31:27.672Z",
      "location_count": 71,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 51 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Sylmar",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04498273"
    },
    {
      "nct_id": "NCT05181683",
      "title": "COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Chronic Stable Illness"
      ],
      "interventions": [
        {
          "name": "Casirivimab+Imdevimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 45,
      "start_date": "2022-01-07",
      "completion_date": "2022-06-03",
      "has_results": false,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-10-07T18:31:27.672Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Winter Park, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05181683"
    },
    {
      "nct_id": "NCT05220397",
      "title": "Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Kidney Transplant Recipient"
      ],
      "interventions": [
        {
          "name": "Janssen Ad26.CoV2.S Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Reduction in Immunosuppression Medication",
          "type": "OTHER"
        },
        {
          "name": "Maintenance in Immunosuppression Medication",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Mark Stegall",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 468,
      "start_date": "2022-04-11",
      "completion_date": "2025-02-28",
      "has_results": true,
      "last_update_posted_date": "2025-09-15",
      "last_synced_at": "2026-10-07T18:31:27.672Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05220397"
    },
    {
      "nct_id": "NCT04519437",
      "title": "Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Chronic Stable Illness"
      ],
      "interventions": [
        {
          "name": "REGN10933+REGN10987",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 974,
      "start_date": "2020-07-26",
      "completion_date": "2021-11-22",
      "has_results": false,
      "last_update_posted_date": "2022-01-26",
      "last_synced_at": "2026-10-07T18:31:27.672Z",
      "location_count": 7,
      "location_summary": "Tempe, Arizona • Rogers, Arkansas • Sacramento, California + 4 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04519437"
    },
    {
      "nct_id": "NCT04432272",
      "title": "ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19",
        "Severe Acute Respiratory Syndrome (SARS)",
        "Coronavirus Infections"
      ],
      "interventions": [
        {
          "name": "COVID-19 convalescent plasma",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Corewell Health East",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2020-07-16",
      "completion_date": "2020-11-28",
      "has_results": true,
      "last_update_posted_date": "2022-03-09",
      "last_synced_at": "2026-10-07T18:31:27.672Z",
      "location_count": 1,
      "location_summary": "Royal Oak, Michigan",
      "locations": [
        {
          "city": "Royal Oak",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04432272"
    },
    {
      "nct_id": "NCT05092581",
      "title": "COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "casirivimab+imdevimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Minute",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Minute to 17 Years"
      },
      "enrollment_count": 2,
      "start_date": "2021-12-16",
      "completion_date": "2022-06-09",
      "has_results": false,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-10-07T18:31:27.672Z",
      "location_count": 2,
      "location_summary": "Stony Brook, New York • Memphis, Tennessee",
      "locations": [
        {
          "city": "Stony Brook",
          "state": "New York"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05092581"
    },
    {
      "nct_id": "NCT04505774",
      "title": "Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "theraputic heparin",
          "type": "DRUG"
        },
        {
          "name": "prophylactic heparin",
          "type": "DRUG"
        },
        {
          "name": "P2Y12",
          "type": "DRUG"
        },
        {
          "name": "Crizanlizumab Injection",
          "type": "DRUG"
        },
        {
          "name": "SGLT2 inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Matthew Neal MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3591,
      "start_date": "2020-09-04",
      "completion_date": "2024-01-26",
      "has_results": true,
      "last_update_posted_date": "2024-12-30",
      "last_synced_at": "2026-10-07T18:31:27.672Z",
      "location_count": 81,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fontana",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04505774"
    }
  ]
}